Dsp-7888
Diffuse Intrinsic Pontine Glioma
Sumitomo Pharma Co., Ltd.vaccinePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Diffuse Intrinsic Pontine Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Actuate Therapeutics Inc. | Phase 2 | BB |
(+)-VINCRISTINE Julie Krystal | Phase 2 | B |
Valproic Acid University of Göttingen | Phase 3 | B |
Ribociclib Nationwide Children's Hospital | Phase 2 | B |
Everolimus Nationwide Children's Hospital | Phase 2 | B |
View all 42 →
Same molecule, other indications
Dsp-7888 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →